Statement from Aaron J. Kowalski, PhD, CEO of Breakthrough T1D, Formerly JDRF, the Leading Global Type 1 Diabetes Research and Advocacy Organization, on NIH Indirect Costs Cuts

NEW YORK, Feb. 9, 2025 /PRNewswire/ — “The announcement from the National Institutes of Health (NIH) that they are dramatically reducing funding for indirect costs for research grants is a threat to research that will disrupt critical medical advances. Funding for indirect costs is…